Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

Abroad (travel likely)Recruiting

Conditions

Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

USD TMO Adulti, Brescia, Italy, Italy

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

Acute Myeloid Leukemia · Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Seattle, United States

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1

Basking Ridge, United States · Middletown, United States

Individualized AML Treatment

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Abroad (travel likely)Recruiting

Duarte, United States

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Relapsed or Refractory Acute Myeloid Leukemia (AML) · Untreated AML · Other IDH1-mutated Positive Hematologic Malignancies

Abroad (travel likely)RecruitingPHASE1

Birmingham, United States · Phoenix, United States